Source: International Congress 2015 – IPF: from bench to bedside
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Nour Bacha (Gournay-Sur-Marne, France), Nour Bacha, Adeline Blandinières, Pascale Gaussem, Chantal Boulanger, Jean Marie Renard, Eduardo Anglès-Cano, Dominique Israël-Biet, David Smadja. Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling. Eur Respir J 2015; 46: Suppl. 59, 3047

Member's Comments

No comment yet.

Related content which might interest you: The ratio AGE/RAGE is increased in idiopathic pulmonary fibrosis Source: International Congress 2015 – Connective tissue disorders Year: 2015 Does apoptosis evasion only affect fibroblasts from idiopathic pulmonary fibrosis? Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013 Club cell secretory protein-CC16 is increased in idiopathic pulmonary fibrosis Source: International Congress 2016 – ILD pathogenesis Year: 2016 Novel biomarkers in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Role of midkine in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Increased levels of oxidative stress markers in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 17(R)-resolvinD1 improves MMP-9/TIMP-1 imbalance leading to amelioration of pulmonary fibrosis in mice Source: International Congress 2016 – ILD pathogenesis Year: 2016 Fibulin-1 is a novel biomarker of disease severity in pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Severe lung inflammation is a feature of IPF Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 The RANKL-OPG balance in pulmonary fibrosis Source: International Congress 2015 – Connective tissue disorders Year: 2015 Role of JAK2/STAT3 pathway in vascular function of pulmonary fibrosis patients Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 Changes in the small airways in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Uncoupling the pro-fibrotic effects of TGF-beta1 versus tissue hardening in lung fibroblasts Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Serum IGFBP2 as a marker of idiopathic pulmonary fibrosis Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 IGFBP-2 a new interesting target in IPF Source: International Congress 2016 – ILD pathogenesis Year: 2016 Tranilast inhibits pulmonary fibrosis by suppressing TGFbeta-mediated extracellular matrix protein production Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Molecular mechanisms of lung tissue remodeling in progression of idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Emerging mechanisms in lung injury Year: 2010 The role of extracellular vesicles in phenotypic alteration of lung cells in pulmonary fibrosis Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury Year: 2013 Prevalence and trafficking of circulating fibrocytes in smoking-related fibrogenic lung diseases Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 Role of dendritic cells in pulmonary fibrosis in mice Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016